iCAD to Report Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28
Rhea-AI Summary
iCAD, a leader in medical technology focused on innovative cancer detection and therapy solutions, will release its financial results for Q4 and the full year ending December 31, 2021, on February 28, 2022, post-market closure. A conference call will follow at 4:30 PM ET, where they will discuss the results. Investors can join the call through domestic and international numbers provided or via a webcast link. For further information about iCAD, visit their official website.
Positive
- Announcement of upcoming financial results may attract investor interest.
- Scheduled earnings call provides transparency and engagement with stakeholders.
Negative
- None.
News Market Reaction – ICAD
In the trading session that priced this news, ICAD gained 7.27%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NASHUA, N.H., Feb. 14, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the fourth quarter and year ended December 31, 2021, after the market close, and host a conference call at 4:30 PM Eastern Time on Monday, February 28.
Monday, February 28th at 4:30 PM ET
| Domestic: | 877-407-0784 |
| International: | 201-689-8560 |
| Conference ID: | 13726987 |
| Webcast: | https://themediaframe.com/mediaframe/webcast.html?webcastid=ELUrpENc |
About iCAD, Inc.
Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions. For more information, visit www.icadmed.com.
Contact:
Media Inquiries:
Jessica Burns, iCAD
+1-201-423-4492
jburns@icadmed.com
Investor Inquiries:
iCAD Investor Relations
ir@icadmed.com
